Sign In
Buy MDWD
$14.12
+0.0200 (+0.142%)
At Close: Jul 31, 2026
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
08:47am, Thursday, 02'nd Mar 2023
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
08:00am, Thursday, 23'rd Feb 2023
YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for
MediWound Ltd. (MDWD) Q3 2022 Earnings Call Transcript
12:30pm, Tuesday, 15'th Nov 2022
MediWound Ltd. (NASDAQ:MDWD ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Monique Kosse - MD, LifeSci Advisors Ofer Gonen - CEO Boaz Gur-Lavie - CFO Conference C
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates
09:47am, Tuesday, 15'th Nov 2022
MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound Ltd. (MDWD) CEO Ofer Gonen on Q2 2022 Results - Earnings Call Transcript
12:31am, Wednesday, 10'th Aug 2022
MediWound Ltd. (NASDAQ:MDWD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - C
MediWound Schedules Second Quarter 2022 Financial Results
08:00am, Monday, 01'st Aug 2022
Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
12:15pm, Tuesday, 17'th May 2022 Zacks Investment Research
MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound Ltd. (MDWD) CEO Sharon Malka on Q1 2022 Results - Earnings Call Transcript
12:04pm, Tuesday, 17'th May 2022
MediWound Ltd. (NASDAQ:MDWD ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Monique Kosse - IR Sharon Malka - CEO Boaz Gur-Lavie - Chief Financial Officer Ofer Gonen -
MediWound Announces CEO Transition
11:01am, Tuesday, 17'th May 2022 GlobeNewswire Inc.
Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
09:47am, Tuesday, 17'th May 2022
MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates
09:25pm, Monday, 16'th May 2022 Zacks Investment Research
Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
09:35pm, Thursday, 12'th May 2022 Zacks Investment Research
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12.33% and 39.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
MediWound Posts Promising EscharEx Data For Chronic Wounds
07:37am, Thursday, 12'th May 2022
MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs). The study met its primary and secondary endpoin
MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
04:01pm, Tuesday, 10'th May 2022
YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and r
